Keilholz, U., & Schadendorf, D. (2002). Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: Second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin. European journal of cancer, 38(11), . https://doi.org/10.1016/S0959-8049(02)00123-5
Chicago-Zitierstil (17. Ausg.)Keilholz, Ulrich, und Dirk Schadendorf. "Prognostic Factors for Survival and Factors Associated with Long-term Remission in Patients with Advanced Melanoma Receiving Cytokine-based Treatments: Second Analysis of a Randomised EORTC Melanoma Group Trial Comparing Interferon-α2a (IFNα) and Interleukin 2 (IL-2) with or Without Cisplatin." European Journal of Cancer 38, no. 11 (2002). https://doi.org/10.1016/S0959-8049(02)00123-5.
MLA-Zitierstil (9. Ausg.)Keilholz, Ulrich, und Dirk Schadendorf. "Prognostic Factors for Survival and Factors Associated with Long-term Remission in Patients with Advanced Melanoma Receiving Cytokine-based Treatments: Second Analysis of a Randomised EORTC Melanoma Group Trial Comparing Interferon-α2a (IFNα) and Interleukin 2 (IL-2) with or Without Cisplatin." European Journal of Cancer, vol. 38, no. 11, 2002, https://doi.org/10.1016/S0959-8049(02)00123-5.